CheckMate 9ER Update Demonstrates Continuous Survival Benefit in RCC With Nivolumab Plus Cabozantinib

Data presented at 2022 ASCO GU of front nivolumab plus cabozantinib for renal cell carcinoma show persistent overall survival benefit versus sunitinib.

Nivolumab (Opdivo) plus cabozantinib (Cabometyx) continues to outperform sunitinib (Sutent) in terms of overall survival (OS) in the setting of frontline renal cell carcinoma (RCC), according to an updated analysis of the CheckMate 9ER trial…

Continue Reading

News Source:

Leave a comment

Your email address will not be published.